Recombinant Bacillus Anthracis Phage-derived Endolysin

N/A

Report date: 2022/08/26 16:55:21

Base Information

Drug NameRecombinant Bacillus Anthracis Phage-derived Endolysin
Drug Alias NameN-Rephasin BAL-200L-alanoyl-D-glutamate endopeptidase from Bacillus-infected bacteriophagesBAL-200
ClassificationBiologics
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsAnthrax
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesIntron Biotechnology Inc
China Registration ClassN/A

Develop Information

Active CompaniesIntron Biotechnology Inc
Inactive CompaniesN/A
Active IndicationsAnthrax
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A